Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667639 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL3404637 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| Alcohol SCHEMBL19231109 | 0.94 | CTSL (0.65) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL3497780 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8520566 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8671997 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054764 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054766 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4369236 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL13669589 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109324128-A | A kind of metabolism group detects general quality-control product and its quality control method | 嘉兴迈维代谢生物科技有限公司 | 2019-02-12 | — | — | CN | claimed |
| WO-2006017619-A2 | RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-09 | — | — | US | claimed |
| CN-113163799-B | Corn protein hydrolysate and preparation method thereof | 嘉吉公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-112837763-A | Structure search method, structure search device, and recording medium | 富士通株式会社 | 2021-05-25 | — | — | CN | disclosed |
| CN-112261939-A | Granzyme B directed imaging and therapy | 塞托赛特生物制药股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2020216240-A1 | DICYCLIC ALKANE COMPOUND USEFUL AS INHIBITOR OF PLASMA KALLIKREIN | 南京明德新药研发有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20030220254-A1 | Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor | TEXAS TECH UNIVERSITY SYSTEM | 2003-11-27 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CA2 1885/4885CA1 1536/4885PTPN1 4824/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CA2 1885/4885CA1 1536/4885PTPN1 4824/4885 |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | ITGB3, ITGB5, ITGA5 | CA2 2656/4885CA1 1817/4885PTPN1 910/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | CA2 1885/4885CA1 1536/4885PTPN1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.